公开(公告)号：US20230117133A1

公开(公告)日：2023-04-20

申请号：US18081603

申请日：2022-12-14

申请人： Myriad Genetics, Inc.

发明人： Victor Abkevich ,  Kirsten Timms ,  Alexander Gutin ,  Julia Reid

IPC分类号： C12Q1/6886

摘要： This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

公开(公告)号：US20230116885A1

公开(公告)日：2023-04-13

申请号：US17966689

申请日：2022-10-14

申请人： Myriad Genetics, Inc.

发明人： Alexander Gutin ,  Julia Reid ,  Ralf Kronenwett ,  Marsel Scheer

IPC分类号： C12Q1/6886 ,  G16H70/60 ,  G16H50/20 ,  G16H20/10 ,  G16B25/10 ,  G16B20/00

摘要： Provided herein are methods for predicting chemotherapy benefit. The invention predicts chemotherapy benefit based on the expression analysis of biomarkers, e.g., RNA biomarker transcription analysis, taken from a tumor sample. The biomarker expression data can be combined with clinical variables, e.g., tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.

公开(公告)号：US11505832B2

公开(公告)日：2022-11-22

申请号：US16809338

申请日：2020-03-04

申请人： MYRIAD GENETICS, INC.

发明人： Alexander Gutin ,  Julia Reid ,  Ralf Kronenwett ,  Marsel Scheer

IPC分类号： C12Q1/6886 ,  G16H70/60 ,  G16H50/20 ,  G16H20/10 ,  G16B25/10 ,  G16B20/00

摘要： Provided herein are methods for predicting chemotherapy benefit. The invention predicts chemotherapy benefit based on the expression analysis of biomarkers, e.g., RNA biomarker transcription analysis, taken from a tumor sample. The biomarker expression data can be combined with clinical variables, e.g., tumor size and nodal status, to generate a profile that predicts the benefit of including chemotherapy as a treatment decision.

公开(公告)号：US20220243276A1

公开(公告)日：2022-08-04

申请号：US17575301

申请日：2022-01-13

申请人： Myriad Genetics, Inc.

发明人： Alexander Gutin ,  Jerry Lanchbury ,  Susanne Wagner ,  Victor Abkevich

IPC分类号： C12Q1/6886 ,  G16H50/20

摘要： Methods and compositions involving molecular markers for the detection and characterization of cancer in a patient are provided.

公开(公告)号：US20220205043A1

公开(公告)日：2022-06-30

申请号：US17493826

申请日：2021-10-04

申请人： Myriad Genetics, Inc.

发明人： Elisha Hughes ,  Alexander Gutin

IPC分类号： C12Q1/6883 ,  G16B25/00 ,  G16B30/00 ,  C12Q1/6827

摘要： The present disclosure relates to methods, kits, and systems for assessing the risk of a human subject for developing a cancer, including genetic risk assessment, clinical risk assessment, and combinations of both to improve risk analysis.

公开(公告)号：US20220205022A1

公开(公告)日：2022-06-30

申请号：US17545611

申请日：2021-12-08

申请人： Myriad Genetics, Inc.

发明人： Alexander Gutin ,  Kirsten Timms ,  Jerry Lanchbury

IPC分类号： C12Q1/6827 ,  G16B30/00 ,  C12Q1/6858 ,  C12Q1/6874 ,  C12Q1/6883

摘要： Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.

公开(公告)号：US11174517B2

公开(公告)日：2021-11-16

申请号：US15349866

申请日：2016-11-11

申请人： Myriad Genetics, Inc.

发明人： Steven Stone ,  Alexander Gutin ,  Julia Reid

IPC分类号： C12Q1/6886

摘要： Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.

公开(公告)号：US20210348240A1

公开(公告)日：2021-11-11

申请号：US17383093

申请日：2021-07-22

申请人： Myriad Genetics, Inc.

发明人： Kirsten Timms ,  Brian Allen ,  Anne-Renee Hartman

IPC分类号： C12Q1/6886 ,  G01N33/574 ,  G16B20/00 ,  C12P19/34 ,  G16B20/10 ,  G16B20/20 ,  A61K31/138

摘要： The invention generally relates to a molecular classification of disease predisposition and particularly to molecular markers for cancer predisposition and methods of use thereof.

公开(公告)号：US20200249243A1

公开(公告)日：2020-08-06

申请号：US16635093

申请日：2018-07-30

申请人： MYRIAD GENETICS, INC.

发明人： Ching Chang HWANG ,  David CHERNOFF ,  Alexander GUTIN ,  Darl FLAKE ,  Jerry LANCHBURY ,  Paul Scott EASTMAN ,  Eric SASSO

IPC分类号： G01N33/68

摘要： Provided herein are methods for assessing response to inflammatory disease therapy. The methods include performing immunoassays to generate scores based on quantitative data for expression of biomarkers relating to inflammatory biomarkers to assess disease activity in inflammatory diseases, e.g., rheumatoid arthritis. Also provided are methods of adjusting disease activity scores to account for variables that can influence such scores.

公开(公告)号：US20200239943A1

公开(公告)日：2020-07-30

申请号：US16815963

申请日：2020-03-11

申请人： MYRIAD GENETICS, INC.

发明人： Alexander Gutin ,  Kirsten Timms ,  Jerry Lanchbury

IPC分类号： C12Q1/6827 ,  C12Q1/6883 ,  C12Q1/6858 ,  C12Q1/6874 ,  G16B30/00

摘要： Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.